No profile data available.
Mereo BioPharma Group plc (MREO) is a healthcare company in the bone and joint treatment drugs industry, based in London, United Kingdom, with about 39 full-time employees.
It reported revenue of $500,000 for fiscal year 2025, and net income of -$41.88 million. Its market capitalization was $55.88 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States.
Mereo BioPharma Group reported $500,000 in revenue for fiscal year 2025.
$55.88 million as of October 9, 2026.
Listed companies of a similar size in the same industry (bone and joint treatment drugs) include Eupraxia Pharmaceuticals Inc. (EPRX), Entera Bio Ltd. (ENTX), Dogwood Therapeutics, Inc. (DWTX), Enlivex Therapeutics Ltd. (ENLV).